---
run_id: halo-evidence-vs-diagnosis-validation-v9-generic-advice-prompted-08
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: generic_advice_prompted
run_number: 8
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 805
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `generic_advice_prompted`, run 8 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 805, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) are being driven by sales incentives (bundle pricing) and roadmap promises, not necessarily by product value. Your usage metrics are being inflated by managers (non-users) and a "novelty spike" among adjusters who eventually revert to manual habits.

The most dangerous signal in your data is the **explainability gap** in the health-liability segment. In a regulated industry, a tool that provides a "correct" answer that cannot be defended to a reviewer is functionally useless.

The other options fail for the following reasons:
*   **Scaling Broadly:** This is premature. You have evidence of "silent churn" (the regional carriers) and a lack of habitual usage. Scaling now would likely increase the volume of "impossible to explain" errors and accelerate churn once bundle pricing expires.
*   **Usage Quality Sprint:** This measures *what* is happening (quantitative) but not *why* it is happening (qualitative). You already know the "what": adjusters stop using it after two days. More dashboards won't tell you why they are reverting to manual notes.
*   **Commercial Cleanroom:** This is a sales experiment, not a product one. While it would prove whether the roadmap pitch is driving renewals, it doesn't fix the underlying product deficiency. You would be testing if people are willing to buy a broken tool, rather than fixing the tool so people want to buy it.
*   **Narrowing to Health-Liability:** This is a premature pivot. You have evidence of struggle in this segment, but you don't yet know if the issue is a fundamental product limitation or a solvable UX/documentation problem.

The **Claim File Review** is the only option that attacks the "ground truth." By seeing exactly where suggestions are overridden or rewritten, you move from guessing why usage drops to knowing exactly which "next actions" are failing. This provides the evidence needed to decide whether to pivot the product or double down on a specific segment.

### The Tradeoff
By choosing the Claim File Review, you are **displacing the Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to definitively prove—via a controlled experiment—how much of your current revenue growth is "artificial" (driven by bundle pricing) versus "organic" (driven by product value). You are choosing to solve the product-market fit problem before solving the pricing-model problem.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and manual. It provides a "snapshot" of a small sample size, whereas the Board typically prefers the perceived certainty of large-scale quantitative data (like the Usage Quality Sprint). There is a risk that the Board views this as "over-analyzing" while the sales momentum is high, potentially viewing your caution as a lack of aggression.

### Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you discovered that the "silent churn" from regional carriers was not due to product utility, but specifically due to a pricing misalignment (e.g., they love the tool but find the bundle price prohibitive). If the problem is *commercial* rather than *functional*, fixing the product won't save the renewals.
